Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 87

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 87
---
 of Company common stock.

We will require additional capital to fund our operations, and
if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates.

We expect to spend substantial capital to complete the development
of, seek regulatory approvals for and commercialize our pharmaceutical product candidates. We are unable to estimate the actual funds
we will require to execute on our strategy because the length of time and activities associated with successful development of our pharmaceutical
product candidates is highly uncertain, and due to the inherent challenges and uncertainties associated with the development of novel
healthcare technologies.

45

The additional capital that we need to fund our operations may
not be available at all, or on terms that allow us to continue operations or provide any hope of generating future profits.

We cannot be certain that additional capital will be available on acceptable
terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly
delay, scale back or discontinue the development or commercialization of any product candidate, delay the launch or expansion of a given
product or potentially discontinue our operations altogether. In addition, attempting to secure additional capital may divert the time
and attention of our management from day-to-day activities and harm our business. Because of the numerous risks and uncertainties
associated with our business, we are unable to estimate the amounts of increased capital outlays, operating expenditures and capital requirements
associated with our current product development programs and technology products.

Our future cash flows from operations are unlikely to satisfy
our capital needs so that we will continue to need to obtain financing through other means that may involve dilution of our stockholders,
limits on our financing activities or reductions of our interest in our subsidiaries and investments.

Until such time, if ever, that we can generate substantial operating
revenues, we expect to continue to finance our cash needs through a combination of equity offerings, debt financings, strategic alliances
and license and development agreements or other collaborations. To the extent that we raise additional capital by issuing equity securities
at the parent or subsidiary level, our existing stockholders’ ownership, or our ownership in our subsidiaries, may experience substantial
dilution, and the terms of these securities may include liquidation or other preferences that could harm the rights of our stockholders.
Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting
our ability to take specific actions